Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 10:14:1235440.
doi: 10.3389/fphar.2023.1235440. eCollection 2023.

Advances in natural products and antibody drugs for SLE: new therapeutic ideas

Yibing Han  1 , Lingwei Liu  1 , Bo Zang  1 , Ruiwen Liang  1 , Xinyue Zhao  1 , Bin Liu  1
Affiliations
Review

Advances in natural products and antibody drugs for SLE: new therapeutic ideas

Yibing Han et al. Front Pharmacol. .

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune systemic disease with a wide range of clinical symptoms, complex development processes, and uncertain prognosis. The clinical treatment of SLE is mainly based on hormones and immunosuppressants. Research on novel therapy strategies for SLE has flourished in recent years, especially the emergence of new targeted drugs and natural products that can modulate related symptoms. This review discusses the current experience including B-cell targeted drugs (belimumab, tabalumab, blisibimod, atacicept, rituximab, ofatumumab, ocrelizumab, obexelimab, and epratuzumab), T-cell targeted drugs (abatacept, dapirolizumab, and inhibitor of syk and CaMKIV), cytokines targeted drugs (anifrolumab and sifalimumab), and natural products (curcumin, oleuropein, punicalagin, sulforaphane, icariin, apigenin, and resveratrol). The aim of this paper is to combine the existing in vitro and in vivo models and clinical research results to summarize the efficacy and mechanism of natural drugs and targeted drugs in SLE for the reference and consideration of researchers.

Keywords: antibody drug; immune system; natural products; systemic lupus erythematosus; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Mechanism of targeted drugs in the treatment of SLE.
FIGURE 2
FIGURE 2
Chemical formulas for natural products effective in the treatment of SLE.
See this image and copyright information in PMC

References

    1. Aggarwal B. B., Harikumar K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell. Biol. 41, 40–59. 10.1016/j.biocel.2008.06.010 - DOI - PMC - PubMed
    1. Almaani S., Meara A., Rovin B. H. (2017). Update on lupus nephritis. Clin. J. Am. Soc. Nephrol. 12, 825–835. 10.2215/cjn.05780616 - DOI - PMC - PubMed
    1. Anand P., Kunnumakkara A. B., Newman R. A., Aggarwal B. B. (2007). Bioavailability of curcumin: Problems and promises. Mol. Pharm. 4, 807–818. 10.1021/mp700113r - DOI - PubMed
    1. Anders H. J., Saxena R., Zhao M. H., Parodis I., Salmon J. E., Mohan C. (2020). Lupus nephritis. Nat. Rev. Dis. Prim. 6, 7. 10.1038/s41572-019-0141-9 - DOI - PubMed
    1. Antony B., Merina B., Iyer V. S., Judy N., Lennertz K., Joyal S. (2008). A pilot cross-over study to evaluate human oral bioavailability of BCM-95cg (biocurcumax), A novel bioenhanced preparation of curcumin. Indian J. Pharm. Sci. 70, 445–449. 10.4103/0250-474x.44591 - DOI - PMC - PubMed

LinkOut - more resources